institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

AI Platforms Produce Melanoma Vaccine Blueprint and Protein Binders for Targeted T-Cell Therapy

CLINICAL SETTINGS AND RESEARCH INSTITUTIONS INCLUDING THE NATIONAL INSTITUTES OF HEALTH, JUL 25 – AI reduces clinical trial screening time by 40% and accelerates personalized cancer immunotherapy development through advanced protein design and precision medicine techniques.

  • Researchers report in Science that an AI system designs protein-based keys guiding immune cells to attack cancer, employing virtual safety screenings to avoid side effects.
  • AI takes over scheduling and data entry tasks, freeing clinicians to focus on patient care, while analyzing large datasets to match patients to trials.
  • Testing revealed that human T cells engineered with the AI-designed protein rapidly killed melanoma cells, and Jenkins says designs can be tested in weeks.
  • AI and ML are already reshaping oncology by accelerating trial timelines, refining treatment selection and enhancing pharmacy operations, with real-time recommendations speeding decisions.
  • The path forward demands collaboration among providers, data scientists, ethicists, regulators, and patients, to advance AI-driven personalized cancer treatments.
Insights by Ground AI
Does this summary seem wrong?

12 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmacy Times broke the news in on Wednesday, July 23, 2025.
Sources are mostly out of (0)